NCT00107549View on ClinicalTrials.gov

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 2009

Conditions
HIV Infections
Interventions
BIOLOGICAL

rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])

Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4

BIOLOGICAL

rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])

Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24

Trial Locations (9)

60614

Chicago Children's CRS, Chicago

90027

Children's Hospital Los Angeles NICHD CRS, Los Angeles

90033

Usc La Nichd Crs, Los Angeles

80218-1088

Univ. of Colorado Denver NICHD CRS, Aurora

Unknown

Univ. of Maryland Baltimore NICHD CRS, Baltimore

Columbia IMPAACT CRS, New York

DUMC Ped. CRS, Durham

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan

38105-2794

St. Jude/UTHSC CRS, Memphis

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00107549 - Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy | Biotech Hunter | Biotech Hunter